在切除后与HBV相关的HCC患者中,特诺福维尔与恩特卡维尔对比
Pengpeng Li1, Yuanyuan Wang1, Jian Yu1
1Third Affiliated Hospital of Naval Medical University, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
JAMA network open
|October 31, 2023
概括
在接受手术的乙型肝炎病毒相关的肝癌患者中,诺福维尔二醇显示出比恩特卡维尔更好的长期结果. 这种抗病毒治疗比较为改善患者存活率和无复发率提供了见解.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 在瘤学瘤学.
- 病毒学 病毒学
背景情况:
- 肝细胞癌 (HCC) 是一个主要的全球健康问题,通常与乙型肝炎病毒 (HBV) 感染有关.
- 诺福维尔迪索普罗克西尔和恩特卡维尔是标准的第一线抗病毒治疗HBV,但它们在肝切除后的比较疗效尚未得到充分证实.
研究的目的:
- 在治疗性肝切除后改善无复发存活率 (RFS) 和整体存活率 (OS) 的方面,比较特诺福维尔二松与恩特卡维尔的有效性,在患有HBV相关的HCC的患者中.
主要方法:
- 一项回顾性队列研究,涉及与HBV相关的肝癌患者,这些患者接受了具有治愈意图的肝切除.
- 倾向性得分匹配 (1:1比率) 用于创建可比的组,接受的是特诺福维尔二醇或恩特卡维尔.
- 分析的重点是比较两组抗病毒治疗组之间的RFS和OS率.
主要成果:
- 与恩特卡维尔相比,诺福维尔二氧化与明显更好的生存率 (HR,0.82;P=.004) 和RFS率 (HR,0.81;P=.001) 有关.
- 在手术后的5年内,特诺福维尔二氧化呈现出更高的OS (64.0%与54.2%) 和RFS (51.4%与43.3%) 率.
- 限制的平均存活时间在5年 (1.82个月长,P=.03) 时,特诺福维尔二氧化组的平均存活时间显着更长.
结论:
- 与乙型肝炎病毒相关的HCC患者接受治疗性肝切除的患者中,诺福维尔迪索普罗克西尔在长期有效性上与恩特卡维尔相比更为优异.
- 这些发现提供了有价值的证据,以指导选择抗病毒疗法,以优化这一患者群体的结果.
- 这项研究强调了抗病毒选择在改善生存率和减少HCC手术后复发的重要性.
更多相关视频
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
5.2K
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
2.3K
相关概念视频
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
